envafolimab   Click here for help

GtoPdb Ligand ID: 10492

Synonyms: Envida® | KN-035 | KN035
Approved drug Immunopharmacology Ligand
envafolimab is an approved drug (China (2021))
Compound class: Antibody
Comment: Envafolimab (KN035) is a chimeric (human/camelid) anti-PD-L1 nanobody that acts as an immune checkpoint inhibitor, and which is being developed by Alphamab Co [1]. Structurally it is a VH-Fc dimer, and does not contain variable light (VL) domains. It therefore has a reduced molecular size and offers more favourable physico-chemical properties than full-size monoclonal antibodies. X-ray crystal structures show that KN035 binds to the same surface on PD-L1 where the ligand interacts with its cognate receptor PD-1 (programmed death protein 1).
The peptide sequence of envafolimab's heavy chain returned no matches with patented peptide sequences in a Protein: BLAST search in September 2019.
Classification Click here for help
Compound class Antibody
Approved drug? Yes (China (2021))
International Nonproprietary Names Click here for help
INN number INN
10930 envafolimab
Synonyms Click here for help
Envida® | KN-035 | KN035
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 934
Other databases
GtoPdb PubChem SID 387065574
Search PubMed clinical trials envafolimab
Search PubMed titles envafolimab
Search PubMed titles/abstracts envafolimab